Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists.
Movement disorders such as Parkinson's disease and Huntington's disease are serious life-limiting and debilitating movement disorders. Their onset typically occurs from mid-life to late in life, and effective diagnostic techniques for detecting and following the disease course are lacking. Our goal is to develop receptor imaging agents for positron emission tomography (PET) that selectively target the most relevant subtype of adenosine receptors (AR) that are highly expressed in the striatum, that is, the A(2A) AR. To further this goal, we have synthesized and characterized pharmacologically a family of high affinity A(2A) AR ligands, based on the known antagonist, SCH 442416 (R=-Me), which have structural variability on the terminus (R=-Et, -i-Pr, -allyl, and others). A O-fluoroethyl analogue suitable for use as a PET tracer had a K(i) value of 12.4 nM and was highly selective for the A(2A) AR in comparison to the A(1) and A(3) ARs.
Shinkre
Bidhan A
BA
Chemical Biology Unit, Laboratory of Cell Biology and Biochemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg 8, Rm 121, NIH, NIDDK, LCBB, Bethesda, MD 20892-0810, United States.
Kumar
T Santhosh
TS
Gao
Zhan-Guo
ZG
Deflorian
Francesca
F
Jacobson
Kenneth A
KA
Trenkle
William C
WC
D058917:Adenosine A2 Receptor Antagonists / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D001665:Binding Sites; D002460:Cell Line; D003198:Computer Simulation; D003287:Contrast Media / Q000138:chemical synthesis* / Q000737:chemistry; D005462:Fluorine Radioisotopes / Q000737:chemistry; D006801:Humans; D049268:Positron-Emission Tomography; D017434:Protein Structure, Tertiary; D011720:Pyrazoles / Q000737:chemistry; D011743:Pyrimidines / Q000138:chemical synthesis / Q000737:chemistry*; D043705:Receptor, Adenosine A2A / Q000737:chemistry* / Q000378:metabolism; D014230:Triazoles / Q000737:chemistry*
D058917:Adenosine A2 Receptor Antagonists; D003287:Contrast Media; D005462:Fluorine Radioisotopes; D011720:Pyrazoles; D011743:Pyrimidines; D043705:Receptor, Adenosine A2A; D014230:Triazoles; C045575:1,2,4-triazole; C030986:pyrimidine; C416650:SCH 442416
Anal Biochem. 1976 May 7;72:248-54
942051
J Med Chem. 2006 Jan 26;49(2):534-53
16420040
Mol Pharmacol. 1994 May;45(5):978-82
8190112
Science. 2008 Nov 21;322(5905):1211-7
18832607
J Med Chem. 2000 Nov 16;43(23):4359-62
11087559
Naunyn Schmiedebergs Arch Pharmacol. 1989 Dec;340(6):679-83
2615857
Bioorg Med Chem Lett. 2007 Mar 1;17(5):1376-80
17236762
Neurology. 2011 May 24;76(21):1811-6
21606452
Cell. 1993 Mar 26;72(6):971-83
8458085
J Pharmacol Exp Ther. 1989 Dec;251(3):888-93
2600819
Trends Neurosci. 2006 Nov;29(11):647-54
17030429
J Pharmacol Exp Ther. 2009 Jul;330(1):294-303
19332567
Expert Opin Investig Drugs. 2009 Nov;18(11):1619-31
19888872
Mol Pharmacol. 1995 Dec;48(6):970-4
8848012
Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):405-13
15549298
J Med Chem. 1998 Jun 4;41(12):2126-33
9622554
J Med Chem. 2007 May 3;50(9):2108-16
17402724
J Med Chem. 1996 Aug 16;39(17):3418-22
8765527
Biochem Pharmacol. 2010 Aug 15;80(4):506-11
20438717